StreetInsider.com News Articles

ProMIS Neurosciences to Participate in Upcoming Conferences and Events in September

Tue, 01 Sep 2026 08:00:00 -0400

CAMBRIDGE, Mass, Sept. 01, 2026 (GLOBE NEWSWIRE) -- ProMIS Neurosciences Inc. (Nasdaq: PMN), a clinical-stage biotechnology company developing antibody therapeutics and vaccines targeting toxic misfolded proteins in neurodegenerative diseases, today announced that it will participate in upcoming September 2026 conferences and key investor events, and will be available for one-on-one meetings.

Conference details below:

September 9-11: Cantor Global Healthcare Conference
Location: New York, NY
Fireside Chat: Wednesday, September 9, 9:10-9:40 a.m. ET
Participants: Pete Stavropoulos, Cantor analyst, and Neil Warma, ProMIS President & Chief

ProMIS Neurosciences to Participate in Upcoming Conferences and Events in September

Tue, 01 Sep 2026 08:00:00 -0400

Conference details below:

Form SCHEDULE 13G/A ProMIS Neurosciences Filed by: GREAT POINT PARTNERS LLC

Fri, 14 Aug 2026 09:35:00 -0400

si-local-file:///var/storage/secattach/20260814/26925875.html

Form SCHEDULE 13G/A ProMIS Neurosciences Filed by: GREAT POINT PARTNERS LLC

Fri, 14 Aug 2026 09:35:00 -0400

si-local-file:///var/storage/secattach/20260814/26925875.html

ProMIS Neurosciences (PMN) PT Raised to $100 at Guggenheim

Fri, 14 Aug 2026 08:37:44 -0400

Guggenheim analyst Eddie Hickman raised the price target on ProMIS Neurosciences (NASDAQ: PMN) to $100.00 (from $69.00) while maintaining a Buy rating.

Form SCHEDULE 13G/A ProMIS Neurosciences Filed by: Wellington Biomedical Innovation Master Investors (Cayman) II L.P.

Thu, 13 Aug 2026 16:30:00 -0400

si-local-file:///var/storage/secattach/20260813/26921810.html

Form SCHEDULE 13G/A ProMIS Neurosciences Filed by: Wellington Biomedical Innovation Master Investors (Cayman) II L.P.

Thu, 13 Aug 2026 16:30:00 -0400

si-local-file:///var/storage/secattach/20260813/26921810.html

Form 8-K ProMIS Neurosciences For: Aug 13

Thu, 13 Aug 2026 16:08:00 -0400

si-local-file:///var/storage/secattach/20260813/26920951.html

Form 8-K ProMIS Neurosciences For: Aug 13

Thu, 13 Aug 2026 16:08:00 -0400

si-local-file:///var/storage/secattach/20260813/26920951.html

Form 10-Q ProMIS Neurosciences For: Jun 30

Thu, 13 Aug 2026 16:07:00 -0400

si-local-file:///var/storage/secattach/20260813/26920897.html

Form 10-Q ProMIS Neurosciences For: Jun 30

Thu, 13 Aug 2026 16:07:00 -0400

si-local-file:///var/storage/secattach/20260813/26920897.html

Form SCHEDULE 13G/A ProMIS Neurosciences Filed by: WELLINGTON MANAGEMENT GROUP LLP

Thu, 13 Aug 2026 16:06:00 -0400

si-local-file:///var/storage/secattach/20260813/26920800.html

Form SCHEDULE 13G/A ProMIS Neurosciences Filed by: WELLINGTON MANAGEMENT GROUP LLP

Thu, 13 Aug 2026 16:06:00 -0400

si-local-file:///var/storage/secattach/20260813/26920800.html

ProMIS Neurosciences Announces Second Quarter 2026 Financial Results and Provides Corporate Highlights

Thu, 13 Aug 2026 16:00:00 -0400

Announced positive blinded six-month interim safety and biomarker results from PRECISE-AD, the Company's Phase 1b trial of PMN310 in patients with early Alzheimer's disease (AD), including zero cases of amyloid-related imaging abnormalities-edema (ARIA-E) across all participants and genotypes, including APOE4 homozygotes.
Observed early, directionally consistent declines in two complementary biomarkers, plasma pTau217 and CSF MTBR-tau243, in a blinded analysis pooling both active- and placebo-treated patients under the trial’s ongoing 3-to-1 randomization.
The second quarter ended with $53.4 million in cash and short-term investments, which is expected to fund operations through 2027, beyond the Company’s anticipated 12-month topline PRECISE-AD

ProMIS Neurosciences Announces Second Quarter 2026 Financial Results and Provides Corporate Highlights

Thu, 13 Aug 2026 16:00:00 -0400

Announced positive blinded six-month interim safety and biomarker results from PRECISE-AD, the Company's Phase 1b trial of PMN310 in patients with early Alzheimer's disease (AD), including zero cases of amyloid-related imaging abnormalities-edema (ARIA-E) across all participants and genotypes, including APOE4 homozygotes.
Observed early, directionally consistent declines in two complementary biomarkers, plasma pTau217 and CSF MTBR-tau243, in a blinded analysis pooling both active- and placebo-treated patients under the trial’s ongoing 3-to-1 randomization.
The second quarter ended with $53.4 million in cash and short-term investments, which is expected to fund operations through 2027, beyond the Company’s anticipated 12-month topline PRECISE-AD

Form 4 ProMIS Neurosciences For: Aug 05 Filed by: Kaplan Johanne

Fri, 07 Aug 2026 16:00:00 -0400
si-local-file:///var/storage/secattach/20260807/26890787.html

Form 4 ProMIS Neurosciences For: Aug 05 Filed by: Kaplan Johanne

Fri, 07 Aug 2026 16:00:00 -0400
si-local-file:///var/storage/secattach/20260807/26890787.html

ProMIS Neurosciences to Report Second Quarter 2026 Financial Results and Business Update on August 13, 2026

Mon, 03 Aug 2026 16:00:00 -0400

Company to host investor conference call and webcast at 4:30 p.m. ET.

Cambridge, Massachusetts, Aug. 03, 2026 (GLOBE NEWSWIRE) -- ProMIS Neurosciences Inc. (Nasdaq: PMN), a clinical-stage biotechnology company developing antibody therapeutics and vaccines targeting toxic misfolded proteins in neurodegenerative diseases, today announced it will report financial results for the second quarter ended June 30, 2026, and provide corporate updates on August 13, 2026.

The company will host a conference call and webcast on the same day of August 13, 2026 at 4:30 p.m. ET.

ProMIS Neurosciences to Report Second Quarter 2026 Financial Results and Business Update on August 13, 2026

Mon, 03 Aug 2026 16:00:00 -0400

Company to host investor conference call and webcast at 4:30 p.m. ET.

Cambridge, Massachusetts, Aug. 03, 2026 (GLOBE NEWSWIRE) -- ProMIS Neurosciences Inc. (Nasdaq: PMN), a clinical-stage biotechnology company developing antibody therapeutics and vaccines targeting toxic misfolded proteins in neurodegenerative diseases, today announced it will report financial results for the second quarter ended June 30, 2026, and provide corporate updates on August 13, 2026.

The company will host a conference call and webcast on the same day of August 13, 2026 at 4:30 p.m. ET.

ProMIS Neurosciences (PMN) PT Raised to $69 at Guggenheim

Wed, 29 Jul 2026 07:14:19 -0400
Guggenheim analyst Eddie Hickman raised the price target on ProMIS Neurosciences (NASDAQ: PMN) to $69.00 (from $35.00) while maintaining a Buy rating.

ProMIS Neurosciences (PMN) PT Raised to $33 at Chardan

Tue, 28 Jul 2026 10:15:15 -0400

Chardan analyst Keay Nakae raised the price target on ProMIS Neurosciences (NASDAQ: PMN) to $33.00 (from $20.00) while maintaining a Buy rating.
The analyst comments "PMN (Buy): Increasing PT to $33 On Encouraging Interim Phase Ib Data. ProMIS Neurosciences has reported positive blinded interim safety and biomarker data at 6-months from the PRECISE-AD phase 1b study evaluating PMN310 in Alzheimer s disease (AD). We believe that this data provides important poof of mechanism that ProMIS' lead mAb asset, PMN-310, is acting as designed. PMN-310 specifically targets soluble toxic Amyloid-β oligomers (AβOs), as they are believed to be highly toxic to neurons,

ProMIS Neurosciences (PMN) PT Raised to $33 at Chardan

Tue, 28 Jul 2026 10:15:15 -0400

Chardan analyst Keay Nakae raised the price target on ProMIS Neurosciences (NASDAQ: PMN) to $33.00 (from $20.00) while maintaining a Buy rating.
The analyst comments "PMN (Buy): Increasing PT to $33 On Encouraging Interim Phase Ib Data. ProMIS Neurosciences has reported positive blinded interim safety and biomarker data at 6-months from the PRECISE-AD phase 1b study evaluating PMN310 in Alzheimer s disease (AD). We believe that this data provides important poof of mechanism that ProMIS' lead mAb asset, PMN-310, is acting as designed. PMN-310 specifically targets soluble toxic Amyloid-β oligomers (AβOs), as they are believed to be highly toxic to neurons,

Form 8-K ProMIS Neurosciences For: Jul 28

Tue, 28 Jul 2026 06:05:00 -0400
si-local-file:///var/storage/secattach/20260728/26821721.html

Form 8-K ProMIS Neurosciences For: Jul 28

Tue, 28 Jul 2026 06:05:00 -0400
si-local-file:///var/storage/secattach/20260728/26821721.html

ProMIS reports no ARIA-E in interim Alzheimer's drug trial data

Tue, 28 Jul 2026 06:00:15 -0400

ProMIS Neurosciences Inc. (Nasdaq: PMN) reported blinded six-month interim safety and biomarker results from its PRECISE-AD Phase 1b trial evaluating PMN310, a drug candidate for mild Alzheimer's disease and mild cognitive impairment due to Alzheimer's disease.

In the interim analysis covering 136 patients, no cases of amyloid-related imaging abnormalities-edema (ARIA-E) were observed across any genotype. Total ARIA incidence was 4.4%, consisting solely of microhemorrhages (ARIA-H), all of which were mild and asymptomatic. No treatment-related serious adverse events or drug-related discontinuations were reported.

The trial population included 61% APOE4 carriers, of which 11% were homozygotes. No ARIA-E was observed in any of these